WCLC 2025: Combination therapy achieves durable response in advanced lung cancer patients
KRAS G12C mutations are among the most common drivers of non-small cell lung cancer (NSCLC), yet first-line targeted therapy options remain limited. Olomorasib, a selective KRAS G12C inhibitor, has shown promising results in combination with chemoimmunotherapy. In an integrated analysis from the Phase I LOXO-RAS-20001 and Phase III SUNRAY-01 trials, Marcelo V. Negrao, M.D., and colleagues examined the safety and preliminary efficacy...
WCLC 2025: Bispecific antibody dose shows promising potential for extensive-stage SCLC
Pumitamig is a novel bispecific antibody targeting both the PD-L1 checkpoint and VEGF, a driver of angiogenesis, being studied in patients...
WCLC 2025: Brigatinib with local therapy can potentially improve outcomes for advanced NSCLC
Almost all patients with ALK-rearranged non-small cell lung cancer (NSCLC) end up with an incomplete response to targeted therapy with tyrosine...
WCLC 2025: Innovative ADC therapy shows promise in hard-to-treat small cell lung cancer
Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat forms of lung cancer, with few effective therapies for patients who relapse. The SEZ6 protein is highly expressed in SCLC and is a promising therapeutic target. In a Phase I study, researchers led by Lauren Byers M.D., evaluated the safety and efficacy of ABBV-706 – an antibody-drug conjugate (ADC) that targets SEZ6 and delivers a chemotherapy...
